Diagnostic Potential of miR-551b-3p in Lung Cancer: In Vitro and In Silico Experiments
Öz
Anahtar Kelimeler
Destekleyen Kurum
Proje Numarası
Kaynakça
- [1]. Leiter, A., Veluswamy, R.R., Wisnivesky, J. 2023. The global burden of lung cancer: current status and future trends. Nature Reviews Clinical Oncology; 20(9):624-639.
- [2]. Çakmak, E. 2022. A bioinformatics approach to identify potential biomarkers in non-small cell lung cancer. Cumhuriyet Science Journal; 43(1):6-13.
- [3]. Yang, Q., Wang, W., Cheng, D., Wang, Y., Han, Y., Huang, J. 2024. Non-coding RNA in exosomes: Regulating bone metastasis of lung cancer and its clinical application prospect. Translational Oncology; 46:102002.
- [4]. Lahiri, A., Maji, A., Potdar, P.D., Singh, N., Parikh, P. 2023. Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer; 22(1):40.
- [5]. Chakrabortty, A., Patton, D., Smith, B.F. 2023. miRNAs: potential as biomarkers and therapeutic targets for cancer. Genes; 14(7):1375.
- [6]. Çakmak, E. 2020. Computational and experimental tools of miRNAs in cancer. Middle East Journal of Cancer; 11(4):381-389.
- [7]. Zhang, Q., Pan, J., Xiong, D., Zheng, J., McPherson, K.N., Lee, S., You, M. 2023. Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention. Frontiers in Immunology; 14:1166951.
- [8]. Cui, Y., Wu, X., Jin, J., Man, W. et al. 2023. CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis. Molecular Cancer; 22(1):179.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Biyomedikal Bilimler ve Teknolojiler
Bölüm
Araştırma Makalesi
Yazarlar
Esen Çakmak
*
0000-0002-9216-7478
Türkiye
Yayımlanma Tarihi
27 Haziran 2025
Gönderilme Tarihi
11 Kasım 2024
Kabul Tarihi
5 Şubat 2025
Yayımlandığı Sayı
Yıl 2025 Cilt: 21 Sayı: 2